AquaBounty Technologies, Inc. (NASDAQ:AQB) Short Interest Update

Posted by Joseph Casey on Apr 17th, 2025

AquaBounty Technologies, Inc. (NASDAQ:AQB – Get Free Report) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totalling 372,800 shares, an increase of 216.7% from the March 15th total of 117,700 shares. Currently, 9.8% of the company’s stock are short sold. Based on an average trading volume of 989,300 shares, the days-to-cover ratio is currently 0.4 days.

AquaBounty Technologies Price Performance

Shares of AQB opened at $0.65 on Thursday. The business’s fifty day moving average is $0.68 and its 200 day moving average is $0.84. AquaBounty Technologies has a 12-month low of $0.47 and a 12-month high of $2.17. The company has a quick ratio of 2.98, a current ratio of 3.02 and a debt-to-equity ratio of 0.05. The stock has a market cap of $2.51 million, a P/E ratio of -0.03 and a beta of 1.27.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in AquaBounty Technologies stock. Epiq Partners LLC lifted its holdings in shares of AquaBounty Technologies, Inc. (NASDAQ:AQB – Free Report) by 423.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 89,000 shares of the company’s stock after acquiring an additional 72,000 shares during the period. Epiq Partners LLC owned approximately 2.30% of AquaBounty Technologies worth $56,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 8.92% of the company’s stock.

About AquaBounty Technologies

(Get Free Report)

AquaBounty Technologies, Inc, a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts.